OncLive SOSS

Clinical Advances in Nasopharyngeal Carcinoma - Episode 4

Value of PD-L1 Biomarker in NPC

August 28, 2024

Barbara Burtness, MD, Victoria M. Villaflor, MD, Shravan Kandula, MD

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma

EP. 3: Overview of the JUPITER and POLARIS-2 Trials

EP. 4: Value of PD-L1 Biomarker in NPC

EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

EP. 9: Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

EP. 10: Clinical Scenario: Locally Recurrent NPC

EP. 11: Clinical Scenario: Metastatic EBV-Positive NPC

Video content above is prompted by the following:

What is the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma?

x